Recombinant Anti-CEA x Anti-DR5 Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-CEA antibody variable domain is fused to CH1 and the other scFv from an anti-DR5 antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can induce targeted apoptosis by activation of the death receptor. It is designed for the research of Breast cancer; Ovary cancer; Colon cancer; Lung cancer therapy.